Cargando…
The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer
The morbidity and mortality caused by endometrial cancer (EC) is still rising worldwide. In recent years, a new system of tumor stratification has been proposed based on POLE-mutational status, TP53, and microsatellite stability status. The aim of the study was to analyze a vast panel on the genes p...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316851/ https://www.ncbi.nlm.nih.gov/pubmed/35885641 http://dx.doi.org/10.3390/diagnostics12071737 |
_version_ | 1784754915338354688 |
---|---|
author | Adamczyk-Gruszka, Olga Horecka-Lewitowicz, Agata Strzelecka, Agnieszka Wawszczak-Kasza, Monika Gruszka, Jakub Lewitowicz, Piotr |
author_facet | Adamczyk-Gruszka, Olga Horecka-Lewitowicz, Agata Strzelecka, Agnieszka Wawszczak-Kasza, Monika Gruszka, Jakub Lewitowicz, Piotr |
author_sort | Adamczyk-Gruszka, Olga |
collection | PubMed |
description | The morbidity and mortality caused by endometrial cancer (EC) is still rising worldwide. In recent years, a new system of tumor stratification has been proposed based on POLE-mutational status, TP53, and microsatellite stability status. The aim of the study was to analyze a vast panel on the genes potentially involved in the genesis of endometrial cancer in the Polish population. One hundred and three white female patients with confirmed endometrial cancer were enrolled on the study. We performed sequencing using the Hot Spot Illumina panel and microsatellite stability with immunohistochemistry. We confirmed a key role of the TP53 mutation in progress to high-grade EC and parallelly some role of FGFR2 mutation. Moreover, our data present a vast landscape of mutations in EC and their polymorphism. We reported the meaning of FGFR2 mutation and TP53 (high copy number) in high-grade ECs. Our observation in MSI contribution is comparable with other studies. Finally, we see a strong need for the implementation of the TCGA classification. |
format | Online Article Text |
id | pubmed-9316851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93168512022-07-27 The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer Adamczyk-Gruszka, Olga Horecka-Lewitowicz, Agata Strzelecka, Agnieszka Wawszczak-Kasza, Monika Gruszka, Jakub Lewitowicz, Piotr Diagnostics (Basel) Article The morbidity and mortality caused by endometrial cancer (EC) is still rising worldwide. In recent years, a new system of tumor stratification has been proposed based on POLE-mutational status, TP53, and microsatellite stability status. The aim of the study was to analyze a vast panel on the genes potentially involved in the genesis of endometrial cancer in the Polish population. One hundred and three white female patients with confirmed endometrial cancer were enrolled on the study. We performed sequencing using the Hot Spot Illumina panel and microsatellite stability with immunohistochemistry. We confirmed a key role of the TP53 mutation in progress to high-grade EC and parallelly some role of FGFR2 mutation. Moreover, our data present a vast landscape of mutations in EC and their polymorphism. We reported the meaning of FGFR2 mutation and TP53 (high copy number) in high-grade ECs. Our observation in MSI contribution is comparable with other studies. Finally, we see a strong need for the implementation of the TCGA classification. MDPI 2022-07-18 /pmc/articles/PMC9316851/ /pubmed/35885641 http://dx.doi.org/10.3390/diagnostics12071737 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Adamczyk-Gruszka, Olga Horecka-Lewitowicz, Agata Strzelecka, Agnieszka Wawszczak-Kasza, Monika Gruszka, Jakub Lewitowicz, Piotr The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer |
title | The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer |
title_full | The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer |
title_fullStr | The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer |
title_full_unstemmed | The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer |
title_short | The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer |
title_sort | roles of tp53 and fgfr2 in progress made treating endometrial cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316851/ https://www.ncbi.nlm.nih.gov/pubmed/35885641 http://dx.doi.org/10.3390/diagnostics12071737 |
work_keys_str_mv | AT adamczykgruszkaolga therolesoftp53andfgfr2inprogressmadetreatingendometrialcancer AT horeckalewitowiczagata therolesoftp53andfgfr2inprogressmadetreatingendometrialcancer AT strzeleckaagnieszka therolesoftp53andfgfr2inprogressmadetreatingendometrialcancer AT wawszczakkaszamonika therolesoftp53andfgfr2inprogressmadetreatingendometrialcancer AT gruszkajakub therolesoftp53andfgfr2inprogressmadetreatingendometrialcancer AT lewitowiczpiotr therolesoftp53andfgfr2inprogressmadetreatingendometrialcancer AT adamczykgruszkaolga rolesoftp53andfgfr2inprogressmadetreatingendometrialcancer AT horeckalewitowiczagata rolesoftp53andfgfr2inprogressmadetreatingendometrialcancer AT strzeleckaagnieszka rolesoftp53andfgfr2inprogressmadetreatingendometrialcancer AT wawszczakkaszamonika rolesoftp53andfgfr2inprogressmadetreatingendometrialcancer AT gruszkajakub rolesoftp53andfgfr2inprogressmadetreatingendometrialcancer AT lewitowiczpiotr rolesoftp53andfgfr2inprogressmadetreatingendometrialcancer |